MindWalk Holdings Corp (NASDAQ:HYFT) stock soared 20.2% in premarket trading Monday following the company’s announcement of a major advancement in its AI-designed GLP-1 therapeutics program.
The Bio-Native AI firm revealed that its LensAI platform has identified a previously unknown link between GLP-1 biology and a second pathway connected to healthy aging and systemic resilience. This discovery lays the groundwork for a first-in-class dual-pathway treatment, in which MindWalk’s proprietary companion therapeutic would be co-administered with its GLP-1 receptor agonists.
According to the company, this development builds on its earlier success in designing GLP-1 receptor agonists entirely through artificial intelligence. MindWalk emphasized that the companion therapeutic is an exclusive asset and not a repurposed product.
“GLP-1 drugs have already transformed diabetes and obesity care, but their potential as Healthspan medicines is only beginning to be recognized,” said Dr. Jennifer Bath, CEO of MindWalk. “By applying HYFT and LensAI, we are not simply iterating on existing drugs—we are uncovering first principles that enable the design of safe, durable GLP-1 analogs and a proprietary companion therapeutic that acts through a complementary longevity pathway.”
Earlier this year, MindWalk reported that its AI-designed GLP-1 peptides matched or outperformed semaglutide—a leading market therapy—in receptor activation assays. The company is now progressing a dual-pathway program combining AI-optimized GLP-1 analogs with its exclusive companion therapeutic.
This move positions MindWalk to tap into the longevity therapeutics market, which the company projects will exceed $60 billion by 2030. Updates on lead selection for the companion therapeutic and preclinical combination design parameters are expected in the coming quarters.
MindWalk Holdings Corp stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.